What the science says about hormone therapy and dementia risk

A renewed public conversation about menopause hormone therapy has put a difficult question back in the spotlight: can these treatments change the odds of dementia later in life?

The short answer from current evidence is that the issue is still unsettled, but the strongest recent reviews do not show clear proof that menopausal hormone therapy prevents dementia. At the same time, newer research has not shown a consistent signal that treatment raises dementia risk overall. That uncertainty is why experts and regulators continue to emphasize individualized decision-making rather than using hormone therapy for brain protection alone.

What happened

Menopause hormone therapy, sometimes called hormone replacement therapy, is commonly used to ease symptoms such as hot flashes, night sweats, and vaginal dryness. It is not a single treatment. Depending on the person and the product, it may include estrogen alone or estrogen paired with a progestogen. The FDA says hormone therapy should not be used to prevent memory loss or Alzheimer’s disease, even though it may help with menopause symptoms. The agency also notes that some products now carry updated labeling after a review of the evidence. https://www.fda.gov/consumers/womens-health-topics/menopause

That labeling change followed growing debate over whether older warnings overstated some risks, including probable dementia. The FDA’s 2026 announcement said it removed boxed-warning language about cardiovascular disease, breast cancer, and probable dementia from certain menopausal hormone therapy products after reviewing the scientific literature. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

Why it matters

Dementia is a major public health concern, and many people want to know whether hormones around menopause influence long-term brain health. That question is especially important because menopause is common, hormone therapy is widely used, and brain-health advice attracts a lot of confident claims that are not always supported by evidence. The NIA says recent findings suggest timing of hormone therapy may matter for Alzheimer’s risk, but the agency also stresses that the data are not yet strong enough to support specific clinical recommendations. https://www.nia.nih.gov/about/2026-nih-alzheimers-disease-and-related-dementias-research-progress-report-advances-and

For readers, the practical significance is simple: hormone therapy may be a reasonable option for symptom relief, but it should not be viewed as a proven strategy to protect memory or prevent dementia. https://www.fda.gov/consumers/womens-health-topics/menopause

What the evidence actually shows

The most important recent synthesis is a 2025 systematic review and meta-analysis in The Lancet Healthy Longevity. It pooled data from 10 studies involving more than 1 million participants and found no significant association between menopausal hormone therapy and the risk of mild cognitive impairment or dementia. It also reported no significant effect in subgroup analyses by timing, duration, or type of therapy. The authors concluded that the review found no evidence that menopausal hormone therapy either increases or decreases dementia risk in postmenopausal women. https://pubmed.ncbi.nlm.nih.gov/41448220/

That does not mean the issue is closed. The review also described the certainty of evidence as ranging from moderate to very low, depending on the outcome and analysis. In plain language, that means the data are not strong enough to settle all the questions people care about, especially around who might benefit, who might be harmed, and whether the timing of treatment matters. https://pubmed.ncbi.nlm.nih.gov/41448220/

Other recent reviews reach a similar bottom line. A 2025 narrative review said current human evidence does not allow clear conclusions about whether hormone replacement therapy changes Alzheimer’s risk and that hormone therapy cannot be recommended as a generic intervention to reduce dementia risk. Another 2025 review focused on cognition similarly described the research as evolving and emphasized that biomarkers and clinical effects remain under active study. https://pubmed.ncbi.nlm.nih.gov/42947097/

What remains uncertain

Several questions still have no definitive answer. Researchers continue to study whether the age at which therapy starts matters, whether the type of hormone or route of administration changes risk, and whether women with different baseline characteristics respond differently. The FDA’s 2025 expert panel specifically highlighted timing, formulation, dose, and duration as open questions. https://www.fda.gov/patients/fda-expert-panels/fda-expert-panel-menopause-and-hormone-replacement-therapy-women-07172025

There is also the issue of study design. Much of the available evidence is observational, which can show associations but cannot prove that hormone therapy itself caused or prevented later dementia. People who use hormone therapy may differ from nonusers in ways that are hard to fully measure, including symptom burden, access to care, medical history, and health behaviors. That makes causal claims risky. https://pubmed.ncbi.nlm.nih.gov/41448220/

At the same time, not every signal in the literature points in the same direction. Some newer observational work suggests lower dementia risk in certain subgroups, such as women with surgical menopause or lower endogenous estrogen exposure, but those findings are not yet enough to change broad guidance. They are best understood as hypotheses for future research rather than proof of a protective effect. https://pubmed.ncbi.nlm.nih.gov/42644405/

Practical context for readers

If menopause symptoms are affecting daily life, hormone therapy may still be worth discussing with a clinician. The best reason to consider it is symptom relief, not dementia prevention. FDA guidance says hormone therapy should not be used to prevent memory loss or Alzheimer’s disease, and MedlinePlus notes that studies do not show it helps treat dementia. https://www.fda.gov/consumers/womens-health-topics/menopause

A clinician can help weigh the type of therapy, dose, route, personal history, and the most relevant risks and benefits. That conversation matters because some products are used systemically, while others are local treatments aimed mainly at vaginal symptoms. The right choice is not the same for everyone. https://www.fda.gov/consumers/womens-health-topics/menopause

It is also worth separating symptom treatment from claims about long-term brain protection. The current evidence does not support hormone therapy as a guaranteed way to preserve memory, delay cognitive decline, or prevent dementia. It also does not support exaggerated fears that it clearly causes dementia in all users. The science is more nuanced than either extreme. https://pubmed.ncbi.nlm.nih.gov/41448220/

The bottom line

Menopause hormone therapy remains an important option for treating menopause symptoms, but its effect on dementia risk is still not fully understood. The best available evidence does not show a clear overall benefit or harm for dementia, and major medical and regulatory sources say it should not be used specifically to prevent memory loss or Alzheimer’s disease. For now, that means the smartest path is individualized care, careful discussion of symptoms and risks, and a healthy skepticism toward headlines that promise more certainty than the science can provide. https://pubmed.ncbi.nlm.nih.gov/41448220/

Next article → Hormone therapy and dementia risk: what the new research really shows